Covid-19: Swiss nasal spray vaccine to enter clinical trials
As a nasal spray the vaccine would be easier to administer, transport and store.
Keystone / Ennio Leanza
A Swiss-led research consortium has partnered with Basel-based biotech company RocketVax to launch clinical trials for two second-generation Covid-19 vaccine candidates. This includes a nasal spray vaccine.
This content was published on
2 minutes
Keystone-SDA/jdp
Español
es
COVID-19: Vacuna suiza en aerosol nasal entrará en fase de ensayo
The research consortium, led by virologist Volker Thiel at the University of Bern, announced on Wednesday that it had signed a partnership with RocketVax to start clinical trials for new vaccine candidates. These are live-attenuated vaccines, which use a form of the virus that doesn’t make people ill but elicits an immune response. Such live vaccines have proven effective against other diseases such as measles.
The Swiss National Science Foundation, which provided funding for the development of the vaccines, said in a press releaseExternal link that the vaccines are intended to be available as a nasal spray, which simplifies administration. It should also be easier to transport and store because the vaccine remains stable at higher temperatures and can therefore be used in warmer climates.
More
More
Many Swiss could prefer wider vaccine choice, survey finds
This content was published on
The representative survey by research group Sotomo, reported in the SonntagsZeitung, was carried out in July, well before the introduction of the Covid certificate obligation this week. However, according to experts interviewed by the paper, it could be a sign that Switzerland’s vaccination campaign would be boosted by making available other jabs which don’t use…
The next step in development is to move to phase I clinical trials (out of typically three phases). If the clinical trials demonstrate the safety and efficacy of the vaccine, the vaccine may be produced in Switzerland.
RocketVax was established in 2020 and is the product of a merger between start-up incubator Swiss Rockets and Gigabases, a biotech spin-off from the federal technology institute ETH Zurich.
The number of new coronavirus infections has risen in the past couple of days, reaching more than 36,000 on Wednesday. The weekly average infection rate is 20% higher than the previous week.
Testing for variants
On Wednesday Basel-based pharmaceutical giant Roche announced that its molecular tests can be used to detect and differentiate Omicron subvariants. This comes as the World Health Organization (WHO) has expressed growing concern about the spread of the BA.2 subvariant.
“It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. This can potentially stop or slow down the advancement of the disease,” said Thomas Schinecker, CEO of Roche Diagnostics, in a press releaseExternal link.
Roche specified that the specific testing solutions detecting variants are available for research use only.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
First large-scale alpine solar plant approved in Switzerland
This content was published on
The approval was met with satisfaction by the project's organisers, but it also brings with it a certain amount of pressure.
Medieval squirrels may have ‘helped spread leprosy’
This content was published on
An examination of squirrel remains in the United Kingdom has opened up interesting questions and possibilities in terms of the history of the disease.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
While Switzerland struggles to vaccinate, Portugal is already finished
This content was published on
Nowhere are more people vaccinated against Covid-19 than in Portugal, where 98% of over 25-year-olds have had both doses.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
Many Swiss could prefer wider vaccine choice, survey finds
This content was published on
The representative survey by research group Sotomo, reported in the SonntagsZeitung, was carried out in July, well before the introduction of the Covid certificate obligation this week. However, according to experts interviewed by the paper, it could be a sign that Switzerland’s vaccination campaign would be boosted by making available other jabs which don’t use…
This content was published on
Public health experts are cautious about lifting Covid-19 restrictions. One key reason is that we still can't test for our immunity to the virus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.